PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.49%
Cost reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive advantage potential.
0.49%
Gross profit growth below 50% of Healthcare median of 1.94%. Jim Chanos would check for business deterioration.
No Data
No Data available this quarter, please select a different quarter.
-36.64%
R&D reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
-70.64%
G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.90%
Operating expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-54.90%
Total costs reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.
54.90%
EBITDA growth exceeding 1.5x Healthcare median of 0.02%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
54.90%
Operating income growth exceeding 1.5x Healthcare median of 5.19%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Other expenses reduction while Healthcare median is -4.31%. Seth Klarman would investigate advantages.
56.85%
Income change of 56.85% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.85%
Income change of 56.85% versus flat Healthcare. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
56.86%
EPS change of 56.86% versus flat Healthcare. Walter Schloss would verify quality.
56.86%
Diluted EPS change of 56.86% versus flat Healthcare. Walter Schloss would verify quality.
-0.00%
Share count reduction while Healthcare median is 0.40%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Healthcare median is 0.31%. Seth Klarman would investigate strategy.